Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database.
Health disparities
Mortality by cause of death
SEER Program
Urinary bladder neoplasms
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
28
06
2022
accepted:
13
02
2023
medline:
8
5
2023
pubmed:
8
3
2023
entrez:
7
3
2023
Statut:
ppublish
Résumé
Previous literature shows that more bladder cancer patients overall die from causes other than the primary malignancy. Given known disparities in bladder cancer outcomes by race and sex, we aimed to characterize differences in cause-specific mortality for bladder cancer patients by these demographics. We identified 215,252 bladder cancer patients diagnosed with bladder cancer from 2000 to 2017 in the SEER 18 database. We calculated cumulative incidence of death from seven causes (bladder cancer, COPD, diabetes, heart disease, external, other cancer, other) to assess differences in cause-specific mortality between race and sex subgroups. We used multivariable Cox proportional hazards regression and Fine-Gray competing risk models to compare risk of bladder cancer-specific mortality between race and sex subgroups overall and stratified by cancer stage. 17% of patients died from bladder cancer (n = 36,923), 30% died from other causes (n = 65,076), and 53% were alive (n = 113,253). Among those who died, the most common cause of death was bladder cancer, followed by other cancer and diseases of the heart. All race-sex subgroups were more likely than white men to die from bladder cancer. Compared to white men, white women (HR: 1.20, 95% CI: 1.17-1.23) and Black women (HR: 1.57, 95% CI: 1.49-1.66) had a higher risk of dying from bladder cancer, overall and stratified by stage. Among bladder cancer patients, death from other causes especially other cancer and heart disease contributed a large proportion of mortality. We found differences in cause-specific mortality by race-sex subgroups, with Black women having a particularly high risk of dying from bladder cancer.
Identifiants
pubmed: 36882598
doi: 10.1007/s10552-023-01679-x
pii: 10.1007/s10552-023-01679-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-531Subventions
Organisme : Division of Cancer Epidemiology and Genetics, National Cancer Institute
ID : SPORE P20CA233216
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
American Cancer Society (2021) Cancer Facts & Figures 2021. ACS, Atlanta
Cárdenas-Turanzas M, Cooksley C, Pettaway CA et al (2006) Comparative outcomes of bladder cancer. Obstet Gynecol 108:169–175. https://doi.org/10.1097/01.AOG.0000223885.25192.91
doi: 10.1097/01.AOG.0000223885.25192.91
pubmed: 16816072
Mungan NA, Aben KK, Schoenberg MP et al (2000) Gender differences in stage-adjusted bladder cancer survival. Urology 55:876–880. https://doi.org/10.1016/s0090-4295(00)00523-9
doi: 10.1016/s0090-4295(00)00523-9
pubmed: 10840099
Scosyrev E, Noyes K, Feng C, Messing E (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115:68–74. https://doi.org/10.1002/cncr.23986
doi: 10.1002/cncr.23986
pubmed: 19072984
Zhai M, Tang C, Li M et al (2020) Short-term mortality risks among patients with non-metastatic bladder cancer. BMC Cancer 20:1148. https://doi.org/10.1186/s12885-020-07655-x
doi: 10.1186/s12885-020-07655-x
pubmed: 33238972
pmcid: 7691110
Wang W, Liu J, Liu L (2021) Development and validation of a prognostic model for predicting overall survival in patients with bladder cancer: a SEER-based study. Front Oncol 11:692728. https://doi.org/10.3389/fonc.2021.692728
doi: 10.3389/fonc.2021.692728
pubmed: 34222021
pmcid: 8247910
Ballas LK, Navarro S, Luo C et al (2021) Disparities in male versus female oncologic outcomes following bladder preservation: a population-based cohort study. Cancer Med 10:3004–3012. https://doi.org/10.1002/cam4.3835
doi: 10.1002/cam4.3835
pubmed: 33779053
pmcid: 8085939
Kaye DR, Canner JK, Kates M et al (2016) Do African American patients treated with radical cystectomy for bladder cancer have worse overall survival? accounting for pathologic staging and patient demographics beyond race makes a difference. Bladder Cancer 2:225–234. https://doi.org/10.3233/BLC-150041
doi: 10.3233/BLC-150041
pubmed: 27376141
pmcid: 4927827
Bhambhvani HP, Zamora A, Shkolyar E et al (2021) Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer. Urol Oncol 39:193.e7-193.e12. https://doi.org/10.1016/j.urolonc.2020.05.009
doi: 10.1016/j.urolonc.2020.05.009
pubmed: 32593506
Wang Y, Chang Q, Li Y (2018) Racial differences in urinary bladder cancer in the United States. Sci Rep. https://doi.org/10.1038/s41598-018-29987-2
doi: 10.1038/s41598-018-29987-2
pubmed: 30591712
pmcid: 6308232
Rosiello G, Knipper S, Palumbo C et al (2020) Rates of other-cause mortality after radical cystectomy are decreasing over time—a population-based analysis over two decades. J Surg Oncol 121:1329–1336. https://doi.org/10.1002/jso.25919
doi: 10.1002/jso.25919
pubmed: 32246846
Bukavina L, Prunty M, Mishra K et al (2020) Gender disparities in bladder cancer-specific survival in high poverty areas utilizing ohio cancer incidence surveillance system (OCISS). Urology. https://doi.org/10.1016/j.urology.2020.07.013
doi: 10.1016/j.urology.2020.07.013
pubmed: 33221419
Noon AP, Albertsen PC, Thomas F et al (2013) Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer 108:1534–1540. https://doi.org/10.1038/bjc.2013.106
doi: 10.1038/bjc.2013.106
pubmed: 23481180
pmcid: 3629420
Registry Groupings in SEER Data and Statistics - SEER Registries. In: SEER. https://seer.cancer.gov/registries/terms.html . Accessed 19 Dec 2021
National Cancer Institute (2021) About the SEER Program. In: SEER. https://seer.cancer.gov/about/index.html . Accessed 11 May 2021
World Health Organization (2021) Classification of Diseases (ICD). In: WHO. https://www.who.int/standards/classifications/classification-of-diseases . Accessed 11 May 2021
National Cancer Institute (2018) SEER Cause of Death Recode 1969+ (03/01/2018) - SEER Data Reporting Tools. In: SEER. https://seer.cancer.gov/codrecode/1969_d03012018/index.html . Accessed 11 May 2021
US Department of Health and Human Services (2020) Smoking Cessation: A Report of the Surgeon General. HHS, Washington
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509. https://doi.org/10.1080/01621459.1999.10474144
doi: 10.1080/01621459.1999.10474144
Fang W, Yang Z-Y, Chen T-Y et al (2020) Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med 18:145. https://doi.org/10.1186/s12967-020-02308-w
doi: 10.1186/s12967-020-02308-w
pubmed: 32228610
pmcid: 7106682
Lee CT, Dunn RL, Williams C, Underwood W (2006) Racial disparity in bladder cancer: trends in tumor presentation at diagnosis. J Urol 176:927–933. https://doi.org/10.1016/j.juro.2006.04.074
doi: 10.1016/j.juro.2006.04.074
pubmed: 16890657
Danforth KN, Luong TQ, Yi DK et al (2020) Disparities in stage at diagnosis in an equal-access integrated delivery system: a retrospective cohort study of 7244 patients with bladder cancer. Clin Genitourin Cancer 18:e91–e102. https://doi.org/10.1016/j.clgc.2019.09.002
doi: 10.1016/j.clgc.2019.09.002
pubmed: 31917174
Radkiewicz C, Edgren G, Johansson ALV et al (2020) Sex Differences in urothelial bladder cancer survival. Clin Genitourin Cancer 18:26-34.e6. https://doi.org/10.1016/j.clgc.2019.10.020
doi: 10.1016/j.clgc.2019.10.020
pubmed: 31787542
Andreassen BK, Grimsrud TK, Haug ES (2018) Bladder cancer survival: women better off in the long run. Eur J Cancer 95:52–58. https://doi.org/10.1016/j.ejca.2018.03.001
doi: 10.1016/j.ejca.2018.03.001
pubmed: 29635144
Washington SL, Neuhaus J, Meng MV, Porten SP (2019) Social determinants of appropriate treatment for muscle-invasive bladder cancer. Cancer Epidemiol Biomarkers Prev 28:1339–1344. https://doi.org/10.1158/1055-9965.EPI-18-1280
doi: 10.1158/1055-9965.EPI-18-1280
pubmed: 31092404
pmcid: 6679737
Schrag D, Hsieh LJ, Rabbani F et al (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95:588–597. https://doi.org/10.1093/jnci/95.8.588
doi: 10.1093/jnci/95.8.588
pubmed: 12697851
Williams SB, Huo J, Kosarek CD et al (2017) Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. Cancer Causes Control 28:755–766. https://doi.org/10.1007/s10552-017-0902-2
doi: 10.1007/s10552-017-0902-2
pubmed: 28477210
pmcid: 5497706
Chase DM, Fedewa S, Chou TS et al (2012) Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy? Obstet Gynecol 119:68–77. https://doi.org/10.1097/AOG.0b013e31823d4006
doi: 10.1097/AOG.0b013e31823d4006
pubmed: 22183213
Liu F, Randall L, Tewari K, Bristow R (2014) Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol 132:221–226. https://doi.org/10.1016/j.ygyno.2013.08.035
doi: 10.1016/j.ygyno.2013.08.035
pubmed: 24016407
Newman LA, Kaljee LM (2017) Health disparities and triple-negative breast cancer in African American women: a review. JAMA Surg 152:485–493. https://doi.org/10.1001/jamasurg.2017.0005
doi: 10.1001/jamasurg.2017.0005
pubmed: 28355428
Robinson JC (1989) Exposure to occupational hazards among Hispanics, blacks and non-Hispanic whites in California. Am J Public Health 79:629–630
doi: 10.2105/AJPH.79.5.629
pubmed: 2631689
pmcid: 1349507
Khanal A, Budhathoki N, Singh VP, Shah BK (2017) Second primary malignancy in bladder carcinoma - a population-based Study. Anticancer Res 37:2033–2036. https://doi.org/10.21873/anticanres.11548
doi: 10.21873/anticanres.11548
pubmed: 28373478
Kwon W-A, Joung JY, Lim J et al (2018) Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea. BMC Cancer 18:617. https://doi.org/10.1186/s12885-018-4530-3
doi: 10.1186/s12885-018-4530-3
pubmed: 29855390
pmcid: 5984459
Rink M, Zabor EC, Furberg H et al (2013) Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 64:456–464. https://doi.org/10.1016/j.eururo.2012.11.039
doi: 10.1016/j.eururo.2012.11.039
pubmed: 23206854
Shiels MS, Gibson T, Sampson J et al (2014) Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage i lung cancers. J Clin Oncol 32:3989–3995. https://doi.org/10.1200/JCO.2014.56.8220
doi: 10.1200/JCO.2014.56.8220
pubmed: 25385740
pmcid: 4251962
Sturgeon KM, Deng L, Bluethmann SM et al (2019) A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 40:3889–3897. https://doi.org/10.1093/eurheartj/ehz766
doi: 10.1093/eurheartj/ehz766
pubmed: 31761945
pmcid: 6925383
Kong J, Diao X, Diao F et al (2019) Causes of death in long-term bladder cancer survivors: a population-based study. Asia Pac J Clin Oncol 15:e167–e174. https://doi.org/10.1111/ajco.13156
doi: 10.1111/ajco.13156
pubmed: 31111675
Stoltzfus KC, Zhang Y, Sturgeon K et al (2020) Fatal heart disease among cancer patients. Nat Commun 11:2011. https://doi.org/10.1038/s41467-020-15639-5
doi: 10.1038/s41467-020-15639-5
pubmed: 32332714
pmcid: 7181822
Zaorsky NG, Churilla TM, Egleston BL et al (2017) Causes of death among cancer patients. Ann Oncol 28:400–407. https://doi.org/10.1093/annonc/mdw604
doi: 10.1093/annonc/mdw604
pubmed: 27831506
Yu J, Lim B, Lee Y et al (2020) Risk factors and outcomes of myocardial injury after non-cardiac surgery in high-risk patients who underwent radical cystectomy. Medicine (Baltimore) 99:e22893. https://doi.org/10.1097/MD.0000000000022893
doi: 10.1097/MD.0000000000022893
pubmed: 33120837
Jun I-J, Kim J, Kim H-G et al (2019) Risk factors of postoperative major adverse cardiac events after radical cystectomy: implication of diastolic dysfunction. Sci Rep 9:14096. https://doi.org/10.1038/s41598-019-50582-6
doi: 10.1038/s41598-019-50582-6
pubmed: 31575918
pmcid: 6773750
Baser S, Shannon VR, Eapen GA et al (2006) Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 130:1784–1790. https://doi.org/10.1378/chest.130.6.1784
doi: 10.1378/chest.130.6.1784
pubmed: 17166997
Simonis K, Shariat SF, Rink M, Urothelial Cancer Working Group of the Young Academic Urologists (YAU), Working Party of the European Association of Urology (EAU) (2014) Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol 24:492–499. https://doi.org/10.1097/MOU.0000000000000079
doi: 10.1097/MOU.0000000000000079
pubmed: 24887046
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89:630–639. https://doi.org/10.1002/1097-0142(20000801)89:3%3c630::aid-cncr19%3e3.3.co;2-h
doi: 10.1002/1097-0142(20000801)89:3<630::aid-cncr19>3.3.co;2-h
pubmed: 10931463
Qin Q, Xu X, Wang X, Zheng X-Y (2013) Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev 14:3117–3121. https://doi.org/10.7314/apjcp.2013.14.5.3117
doi: 10.7314/apjcp.2013.14.5.3117
pubmed: 23803089
Sun J-W, Zhao L-G, Yang Y et al (2015) Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One 10:e0119313. https://doi.org/10.1371/journal.pone.0119313
doi: 10.1371/journal.pone.0119313
pubmed: 25803438
pmcid: 4372289
Lu Y, Tao J (2021) Diabetes mellitus and obesity as risk factors for bladder cancer prognosis: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 12:699732. https://doi.org/10.3389/fendo.2021.699732
doi: 10.3389/fendo.2021.699732
pubmed: 34690923
pmcid: 8529220
National Cancer Institute (2018) SEER*Stat Software. In: SEER. https://seer.cancer.gov/seerstat/index.html . Accessed 22 Jun 2022